2008: RA Treatment Strategies and Treatment Safety
Search or Browse by Day

RA Treatment Strategies and Treatment Safety

Tuesday, October 28, 2008
1639
Increased Adipsin and Low Leptin Levels are Associated with Higher Remission Rates in Early RA Patients Treated with a Combination of DMARDs (NEO-RACo study)
1640
Evaluation Of Two Strategies (initial Methotrexate Monotherapy Versus Its Combination With Adalimumab) In Management Of Early Active Rheumatoid Arthritis During The First Year Of Evolution: Data From The Guepard Trial
1641
Similar results of aggressive and conventional therapy in the first year of the STRategies in Early Arthritis Management (STREAM) study
1642
Disease Activity Score (DAS) and Health Assessment Questionnaire (HAQ) Values Show Similar Changes from Baseline to Endpoint in Clinical Trials of Biological Agents in Patients with Rheumatoid Arthritis (RA)
1643
Corticosteroid-responsive Pharmacodynamic Transcriptional Markers: Results From A Randomised Placebo-controlled Study Of Rheumatoid Arthritis Patients Treated With Prednisolone
1644
Systemic TNFSFR9 Levels In RA Patients Correlate With Disease Activity: Clinical And Pre-clinical Validation Of A Novel Biomarker
1645
The Beneficial Effects Of A 3 Week Course Of Im Steroid Injections In Very Early Inflammatory Polyarthritis: Results Of The Stivea Trial
1646
Dose Patterns and Health Plan Costs among RA Patients Treated with Tumor Necrosis Factor Antagonists
1647
Switching Tnf Inhibitors And Immunogenicity In Rheumatoid Arthritis (RA)
1648
Two-Year Longitudinal Study of Persistence To Anti-Tumor Necrosis Factor Treatment Among Rheumatoid Arthritis Patients
1649
Very Early Improvement in Hand Function Predicts Favourable Response in RA Patients Treated With Adalimumab
1650
Pharmacogenomics of Anti-TNF Treatment in Rheumatoid Arthritis Reveals an Active Baseline TNF Response Profile in All Patients
1651
Detection Of Anti-infliximab Antibodies Is Of Limited Value To Predict Acquired Drug Resistance To Infliximab In Rheumatoid Arthritis
1652
Serum Markers Associated With Improvement In Clinical Response Measures In RA Patients Treated With Golimumab, A New Human Anti-TNFα Monoclonal Antibody
1653
IL-1 Gene Signature Is Able To Predict The Responsiveness To Anakinra
1654
Methotrexate (MTX), Ethanol And The Liver; Adenosine And Its Receptors Play A Central Role In Fatty Liver
1655
Leflunomide is as effective in Combination with TNFα Antagonists as MTX, but has more Side Effects: Results from a Case-Control-Study
1656
Effectiveness of TNF Inhibitors in RA Patients with Moderate vs High Disease Activity
1657
Risk of Elevated Liver Enzymes (LFTS) with TNF Inhibitors (TNF-I) in Rheumatoid Arthritis: Analysis in 6,861 Patients with 22,552 Visits
1658
T-cell Responses To Epstein-barr Virus Antigens Are Not Impaired By Anti-TNFα Treatments
1659
Performance of QuantiFeron in Screening for Latent Tuberculosis in Rheumatoid Arthritis Patients Undergoing Anti-TNF Therapy
1660
Serious Infections During Anti-TNF Treatment in RA Patients: Clinical Practice Experience
1661
Is The Incidence Risk Of Cancer Constant Through Time In Rheumatoid Arthritis Patients Exposed to Biologics?
1662
Is Psoriasis a complication of Anti-TNF Treatment?
1663
Retinal Toxicity Due To Etanercept
1664
Etanercept Therapy in Rheumatoid Arthritis and the Risk of Malignancy: A Systematic Review and Individual Patient Data-Based Meta-analysis of Randomized Controlled Trials
1665
The Risk Of Lymphoma Is Higher In Patients Treated With Infliximab Or Adalimumab Than In Patients Treated With Etanercept. Results Of The French 3-year Prospective Ratio Observatory
1666
Duration Of Anti-tnf Exposure And Lymphoma Risk
1667
Hepatic Aminotransferases and Bilirubin Levels During Tocilizumab Treatment of Patients with Rheumatoid Arthritis: Pooled Analysis of Five Phase 3 Clinical Trials
1668
Relationship Between Patient Characteristics and the Development of Serious Infections in Patients Receiving Tocilizumab: Results from Long-term Extension Studies with a Follow-up Duration of 1.5 Years
1669
Safety of Tocilizumab in Patients with Rheumatoid Arthritis: Pooled Analysis of Five Phase 3 Clinical Trials
1670
Safety of Tocilizumab in Patients with Rheumatoid Arthritis: An Interim Analysis of Long-Term Extension Trials with a Mean Treatment Duration of 1.5 Years
1671
Safety Of Other Biologic Therapies Following Rituximab Treatment In RA Patients
1672
Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis with Elevated Low Density Lipoprotein Cholesterol: Analysis of Five Phase 3 Clinical Trials
1673
Autoimmune Adverse Events in the Abatacept RA Clinical Development Program: A Safety Analysis with > 10,000 Person-years of Exposure
1674
Hospitalized Infections in the Abatacept RA Clinical Development Program: An Epidemiological Assessment with > 10,000 Person-years of Exposure
1675
Malignancies in the Abatacept RA Clinical Development Program: An Updated Epidemiological Assessment with > 10,000 Person-years of Exposure
See more of: ACR Abstract Submission Poster Sessions
<< Previous Session Level | Next Session Level >>